首页> 外文期刊>Current Opinion in Molecular Therapeutics >Technology evaluation: ISIS-104838, OraSense.
【24h】

Technology evaluation: ISIS-104838, OraSense.

机译:技术评估:ISIS-104838,OraSense。

获取原文
获取原文并翻译 | 示例
           

摘要

OraSense Ltd (a joint venture between Isis Pharmaceuticals Inc and Elan Corp) is developing ISIS-104838, an antisense oligonucleotide specific for TNF alpha mRNA, as an inhibitor of TNF alpha synthesis. The compound is being developed for the potential treatment of inflammatory diseases such as rheumatoid arthritis, Crohn's disease and psoriasis. This antisense oligonucleotide is currently undergoing phase II clinical trials for RA and Crohn's disease.
机译:OraSense Ltd(Isis Pharmaceuticals Inc和Elan Corp之间的合资企业)正在开发ISIS-104838,这是一种针对TNFαmRNA的反义寡核苷酸,可作为TNFα合成的抑制剂。该化合物正在开发中,可用于治疗炎症性疾病,例如类风湿性关节炎,克罗恩病和牛皮癣。该反义寡核苷酸目前正在针对RA和克罗恩氏病进行II期临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号